Useful serum surrogate biomarkers have not been identified for DMD, and both MR imaging biomarkers and measures of dystrophin expression on muscle biopsy have not been validated sufficiently to be employed as primary clinical trial endpoints. This evidence concerns the gene DMD and Duchenne muscular dystrophy.